Evofem Biosciences Inc. [NASDAQ: EVFM] loss -7.06% or -0.02 points to close at $0.21 with a heavy trading volume of 5028953 shares. The company report on April 19, 2022 that Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem’s Phase 3 AMPOWER Clinical Trial.
88.7% of Women Using Phexxi® (lactic acid, citric acid, and potassium bitartrate Vaginal Gel) Improved or Maintained their Sex Life According to Exploratory Data Collected During the Phase 3 AMPOWER Clinical Trial.
Women in the Study Provided Data Measured by 10 Variables Ranging from the Ability to Climax to Interest in Having Sex.
It opened the trading session at $0.233, the shares rose to $0.2343 and dropped to $0.2065, the range by which the price of stock traded the whole day. The daily chart for EVFM points out that the company has recorded -69.79% loss over the past six months. However, it is still 4.55% higher than its most recent low trading price.
If we look at the average trading volume of 2.74M shares, EVFM reached to a volume of 5028953 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Evofem Biosciences Inc. [EVFM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVFM shares is $1.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVFM stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 02, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $3, while Morgan Stanley analysts kept a Equal-Weight rating on EVFM stock.
The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.02, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 4.96.
Trading performance analysis for EVFM stock
Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.14. With this latest performance, EVFM shares dropped by -45.04% in over the last four-week period, additionally sinking by -69.79% over the last 6 months – not to mention a drop of -86.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 19.94, with the RSI for the last a single of trading hit 13.44, and the three-weeks RSI is set at 26.05 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 0.3782, while it was recorded at 0.2267 for the last single week of trading, and 0.5799 for the last 200 days.
Evofem Biosciences Inc. [EVFM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -2023.30 and a Gross Margin at +21.37. Evofem Biosciences Inc.’s Net Margin is presently recorded at -2488.99.
Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
An analysis of insider ownership at Evofem Biosciences Inc. [EVFM]
There are presently around $5 million, or 18.50% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: VANGUARD GROUP INC with ownership of 6,860,966, which is approximately -2.124% of the company’s market cap and around 1.50% of the total institutional ownership; BLACKROCK INC., holding 3,921,774 shares of the stock with an approximate value of $0.91 million in EVFM stocks shares; and BAKER BROS. ADVISORS LP, currently with $0.62 million in EVFM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 22 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 1,669,338 shares. Additionally, 31 investors decreased positions by around 4,875,336 shares, while 27 investors held positions by with 16,993,024 shares. The mentioned changes placed institutional holdings at 23,537,698 shares, according to the latest SEC report filing. EVFM stock had 9 new institutional investments in for a total of 200,134 shares, while 17 institutional investors sold positions of 1,434,411 shares during the same period.